Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 16 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
ERC Pharma from Gembloux, company number BE1002131150, closed financial year 2025 with a result of € -179,975 after tax. For that financial year ERC Pharma recorded a gross margin of € -60,682 and equity of € -231,937. Compared with financial year 2024, the result moved from € -151,962 to € -179,975. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.
€ -231,937
▼ € 179,975 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -179,975
▼ 18 % more loss than in 2024
Profit after tax over the fiscal year.
Loss, nothing to pay out
Reserves fell to € -331,937.
Debts at end 2025
€ 2 million
▼ 7% vs 2024
€ 364,020 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 98,708
▲ € 97,617 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 3,348
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € -49,253 | € -60,682 | ▼ € 11,429 |
| Profit after taxes | € -151,962 | € -179,975 | ▼ € 28,013 |
| Equity | € -51,962 | € -231,937 | ▼ € 179,975 |
| Total debts | € 3,751,141 | € 3,790,114 | ▲ 1% |
| Cash | € 36 | - | |
| Land & buildings | € 590,104 | € 575,427 | ▼ 2% |
| Retained profit | € -151,962 | € -331,937 | ▼ € 179,975 |
| Bank debt | € 2,210,790 | € 2,049,545 | ▼ 7% |
| Balance sheet total | € 3,699,179 | € 3,558,176 | ▼ 4% |
Key figures of ERC Pharma, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ERC Pharma?
What happened at ERC Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 179,975. filed late Source: NBB ↗
- New establishment in Gembloux. KBO
- Start of the company according to the CBE. KBO
In short
From € 151,962 loss in 2024 to € 179,975 loss in 2025.
Establishments
Establishment units
Physical locations of this company
Rue Jean Sonet,Isnes 10
5032 Gembloux
Rue Jean Sonet,Isnes 10 box 3
5032 Gembloux
Active since 1 January 2024
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1002.131.150
- VAT number
- BE 1002.131.150
- Registered office
- Rue Jean Sonet,Isnes 10, 5032 Gembloux
- Names & denominations
- ERC Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 9 November 2023
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- [email protected] +3281728610
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Detailhandel in farmaceutische producten